Medical Devices & Equipment Company

CYduct Diagnostics, Inc.

To find out if this company and others are accepting funding, .

Funding Goal
Funding Raised So Far
Funding Commitments
Funding Remaining
Funding Type
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

CYduct Diagnostics, Inc., OTC: CYDX (“CYductDX"), is headquartered in Westport, Connecticut, the company develops, produces, and markets medical devices for the early assessment, identification, diagnosis and ultimately treatment of breast cancer.

Read More
lock icon

Unlock Company Profile

Sign up now to unlock full company profiles and access financials, investor documents, and engage companies.

Business Summary

Company Age 3 years, 11 months
Employees 3
Sub-Industry Diagnostic
Prior Year Revenue
Current Year Revenue
Next Year Revenue


Breast Healthcare Technologies

CYductDX has and is developing technology that will Improve breast wellness through intraductal procedures and imaging devices for accurate assessment, diagnosis and treatment of diseases in the breast, primarily breast cancer.

The Company will offer the first proprietary proteomic Point-of-Care individualized molecular-based (biomarker) breast health test that analyzes nipple aspirate fluid (NAF). NAF contains the cellular, genetic and metabolic information produced by the breast of the individual tested. CYduct technology is the gateway to a new standard of personalized risk assessment, surveillance, diagnosis and ultimately, treatment of breast disease.


Chief Executive Officer
Dom Gatto

Founder of CYductDX, his professional experience includes many different areas ranging from product management to executive management for over ten start-up entities. He was previously the chief operating officer for start-up Acueity Healthcare, a revolutionary technology for early detection of breast cancer. During his career, he has developed, launched and successfully managed over 75 medical devices ranging from polymer-based disposables to integrated imaging systems. He holds 7 patents and is co-inventor on three patent pending medical devices. Mr. Gatto graduated Magna Cum Laude with a BS degree in Marketing from Quinnipiac University and attended the Executive Management program at the John E. Anderson School of Business – UCLA. He is currently a judge, mentor and Entrepreneur-in-Residence at The University of Notre Dame’s Mendoza School of Business. Also, he has worked as an entrepreneurial advisor for the NFL Player Engagement Program.

Chief Operating Officer
Michael R. Stewart

Michael Stewart is a seasoned and results-oriented executive with 29 years of experience in medical device company C-level positions and nearly 40 years’ experience in executive management, operations and finance. He brings a wealth of expertise with particular strength in operations, financial management, strategy, M&A, capital raise, FDA matters, medical reimbursement as well as sales, marketing, product development and product launch. Mike is a critical thinker and adept negotiator with extensive U.S. and International market expertise and has significant experience with public company board and SEC matters. Prior to joining CYduct, Michael operated as a private consultant to multiple companies which he started in late 2016. He has worked with companies from private start-up to mid-size public companies assisting them with major negotiations, new product and company launches, merger and acquisitions and capital raises.

Chief Financial Officer
Claus Madsen

Mr. Madsen’s career in finance and accounting began when he joined Arthur Andersen & Co. (AA). He earned his CPA certification and reached the level of Senior Manager. At AA, He worked in the real estate and construction practice. Clients included large multi-family residential developments, home builders, commercial real estate developers and managers and real estate syndicators. In addition, Mr. Madsen has industry experience in leasing, banking and health care. Following departure from AA, he was recruited to join Babcock and Brown Inc. (BBI), an international asset-based financing company. As Corporate Controller at BBI, he gained valuable experience in the day-to-day operation of the administrative functions of the company, in addition to budgets and cost control, and board reporting and presentations. His next challenge was as Chief Financial Officer at Acueity, Inc., a start-up medical device company

Chief Physician/Medical Officer
Darius Francescatti

Dr. Francescatti is an Assistant Professor of Surgery and a board-certified General Surgeon with University Surgeons, section of Breast Oncology, at Rush Medical Center in Chicago Illinois. Born and raised in Chicago, he enlisted in the United States Air Force where he earned an honorable discharge. He then entered Loyola University and received a Bachelor of Science degree in Biology. Admission to Stritch Medical School followed where he received his Medical Degree. His expertise in both the diagnosis and treatment of breast cancer led to his resignation from Gessler, Hughes and Sokal and acceptance of a full-time position at Rush Medical Center with University Surgeons where he remains in practice. Dr. Francescatti is member of both the American College of Surgeons and The American Society of Breast Surgeons.

Chief Science/Scientist
Chris Sutton, Ph.D.

Chris Sutton obtained a Ph.D. in Biochemistry from University of Liverpool, with combined studies in the Department of Molecular Biology, University of California, Berkeley. He was then a Postdoctoral Research Scientist at the London School of Hygiene and Tropical Medicine, investigating the mechanisms of pathogenicity of Vibrio cholerae. He joined the premier of UK biotechnology company, Celltech Limited, as a Senior Scientist in Protein Biochemistry purifying novel proteins of therapeutic interest and was later promoted to Group Leader of Analytical Biochemistry. With the emergence of mass spectrometry for protein characterization, he moved to ThermoFinnigan and developed novel applications for matrix assisted laser desorption mass spectrometry (MALDI MS) including pioneering work in proteomics.


To find out if this company and others are accepting funding, .

Funding Goal
Funding Raised So Far
Funding Commitments
Funding Remaining
Funding Type
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding



CYduct Diagnostics, Inc.

Westport, CT 06880, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).